Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025 Largest global clinical trial in pediatric myopia ...
Abstract: Modeling and controlling aircraft can be particularly challenging when the system is highly nonlinear or only partially understood. While data-driven approaches can be promising in this ...
Use topic modeling on News API data to spot rising themes faster than rivals and act before the market shifts. Clean your articles, pick an algorithm like LDA, tune the number of topics, and label ...
WALTHAM, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...
Data support the potential therapeutic efficacy of ROC-101; justify further development via a Phase 2, proof-of-concept trial in patients with PAH or ILD-PH slated to begin Q4 2025 NATICK, Mass., Sept ...
At the beginning of August, the United States Patent and Trademark Office (USPTO) sent a memo on patent eligibility rejections to Technology Centers 2100, 2600 and 3600. Written by Deputy Commissioner ...
Positive results released from updated data with 17 SCD patients with VOC from the phase 1/2 BEACON study. No VOC after engraftment and >60% HbF induction. Additional results of 30 SCD patients from ...
Background: Endometrial cancer (EC) is a common and increasingly prevalent gynecological malignancy. Pyroptosis, a pro-inflammatory form of programmed cell death, plays dual roles in cancer but ...
Jade Biosciences, Inc. announced that new preclinical data on its investigational anti-APRIL monoclonal antibody, JADE101, will be presented at the 62nd European Renal Association Congress in Vienna ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback